Onconetix, Inc.
ONCO Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$0.42
KIRA · Stoqly’s AI analyst, in plain words
- Onconetix, Inc. had $0.8M of revenue in fiscal 2025, down 67.7% on the year before.
- Its operating margin was −2,190.0%, up 48.0 pts: of every 100 in sales, about −2,190 is left after running the business.
- Onconetix, Inc. lost $14.0M in fiscal 2025.
Market cap
$0.9M
P/E
0.0x
Revenue
$0.8M
Net income
−$14.0M
Free cash flow
—
Operating margin
−2,190.0%
Onconetix, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−67.7%
No. Sales fell 67.7% last year.
Does it make a profit?
−1,720.9%
No. It lost money last year.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
0.0x
One share costs 0.0 times its yearly profit per share.
What Onconetix, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 13, 2026
- Legal name
- Onconetix, Inc.
- CIK
- 0001782107
Onconetix, Inc. · ONCO
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | — | $0.1M | $2.5M | $0.8M |
| Revenue growth | — | — | — | 4,214.7% | −67.7% |
| Gross margin | — | — | −1,926.8% | 41.8% | 77.6% |
| Operating margin | — | — | −61,597.6% | −2,238.0% | −2,190.0% |
| Net income | −$3.4M | −$13.4M | −$37.4M | −$58.7M | −$14.0M |
| Net margin | — | — | −63,948.2% | −2,325.2% | −1,720.9% |
| Diluted EPS | −$1.26 | −$1.10 | −$87.45 | −$1,823.39 | −$16.56 |
| Cash | |||||
| Cash from operations | −$2.0M | −$8.7M | −$13.6M | −$10.5M | −$9.7M |
| Capital expenditure | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Free cash flow | −$2.0M | −$8.7M | −$13.6M | −$10.5M | — |
| FCF margin | — | — | −23,221.0% | −417.0% | — |
| Share buybacks | — | $0.6M | — | — | — |
| Share count change | — | 283.5% | −96.5% | −92.4% | 2,803.1% |
| Debt and strength | |||||
| Cash and short-term investments | $1.9M | $25.8M | $4.6M | $0.6M | $5.2M |
| Deposits | — | — | $3.5M | $3.5M | — |
| Shareholders' equity | $1.4M | $22.4M | −$5.6M | $8.5M | $15.8M |
| Current ratio | 1.9x | 6.7x | 0.3x | 0.1x | 0.7x |
| Interest coverage | — | — | −53.7x | −64.7x | −23.8x |
| Returns and quality | |||||
| Return on equity | −236.2% | −112.6% | −445.7% | −3,991.8% | −115.5% |
| Return on tangible equity | −279.6% | −60.4% | — | — | — |
| Piotroski F-score | — | — | — | 4 | 4 |
| Altman Z'' | −9.8 | 5.7 | −6.0 | −30.4 | −21.0 |
Insiders bought, 12 months
$0.2M
1 insider
Insiders sold, 12 months
$0.1M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Onconetix, Inc. · ONCO
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.42 a share, the company is worth $0.9M: 0.0 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001782107). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.